arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Inhibikase Therapeutics, Inc.

IKT

$1.44 ▼ -0.12 (-7.99%) at close

7 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Inhibikase Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $141.6M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -30.1% →

FCF / Share $-0.28 ↗

Trailing P/E —

Price / Book 1.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$260.50K

↑ +111.0% —

Net Income Profit after all expenses

$-48.26M

↓ -75.4% —

Operating Margin Operating profit as % of sales

-476.2%

↓ -18.0% —

FCF / Share Free cash flow per share

$-0.28

↑ +65.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	111.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1288%)	-96.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1300%)	343.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4199%)	—	—
EPS Growth YoY (%)	57.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	67.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	16.6% Good Good Year-over-year change in earnings per share Optimal: > 10%	-428.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-75.4% Weak ↓ Weak Declining Year-over-year change in net income	-44.6% Weak ↑ Weak Improving Year-over-year change in net income	-5.4% Weak ↑ Weak Improving Year-over-year change in net income	-22.1% Weak Weak Year-over-year change in net income	-419.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	65.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	76.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.5% Good Good Year-over-year change in free cash flow	-430.6% Weak Weak Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	—	—	-28.0% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-476.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3275%)	-403.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2790%)	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	-476.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4074%)	-407.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3498%)	—
FCF Margin (%) (%)	—	—	—	—	-461.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-161.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.58x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-30.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-139.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-68.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-22.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-138.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-72.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-27.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-286%)	-29.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	-173.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1256%)	-85.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-672%)	-38.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-357%)	-29.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-294%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	—	—	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-94%)	—	—	—	—
Interest Coverage (x)	—	—	—	-18631.66x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12862.49x Weak Weak Operating income divided by interest expense Optimal: > 5x	-95.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-178.80M	$-97.50M	$-8.79M	$-7.19M	$-40.75M	—	—
Debt / EBITDA (x)	—	—	-0.02x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	$0.05	$0.03	$0.17	—	—
Basic EPS, GAAP (USD)	$-0.49	$-1.16	$-3.57	$-4.28	$-0.81	—	—
Free Cash Flow per Share (USD)	$-0.28	$-0.81	$-3.39	$-4.17	$-0.79	—	—
Book Value per Share (USD)	$1.31	$1.37	$1.77	$4.98	$1.53	$0.97	—
Tangible Book Value per Share (USD)	$1.31	$1.37	$1.77	$4.98	$1.53	$0.97	—
Basic Weighted Avg Shares (shares)	98.31M	23.71M	5.33M	4.22M	18.21M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$171.81M	$94.72M	$10.77M	$20.68M	$38.42M	—	—
LT Debt (USD)	—	—	$381.78K	—	—	—	—
Total Equity (USD)	$172.90M	$94.87M	$10.98M	$21.04M	$38.42M	$9.78M	$-4.49M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$260.50K	$123.44K	$3.10M	$698.47K	—
Depreciation Expense (USD)	$60.50K	$26.27K	$177.40K	$6.72K	$0.00	—	—
Net Income, GAAP (USD)	$-48.26M	$-27.52M	$-19.03M	$-18.05M	$-14.79M	$-2.85M	—
Operating Cash Flow (USD)	$-27.79M	$-19.15M	$-18.09M	$-17.35M	$-14.30M	$-1.13M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Inhibikase Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IKT with peers